Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects

AIDS

Volumn 12, Issue 2, 1998, Pages 175-182

  Kelleher, Anthony D ^a,e   Roggensack, Monika ^a   Jaramillo, Angel B ^a   Smith, Don E ^a   Walker, Alan ^a   Gow, Irene ^b   McMurchie, Marilyn ^c   Harris, Jan ^b   Patou, Gary ^b   Cooper, David A ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b British Biotechnology   (United Kingdom)

^c Natl Ctr HIV Epidemiol Clin Res ^*

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Activation; Immunogenicity; Vaccine; Viral load; Zidovudine

Indexed keywords

ADJUVANT; CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; AIDS VACCINES; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VIRAL LOAD; ZIDOVUDINE;

EID: 6844241948     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199802000-00007     Document Type: Article

References (38)

1. Salk J: Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987, 327:473-476.
2. Redfield RR, Birx DL, Ketter N, et al.: A Phase 1 evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991, 324:1677-1684.
3. Wahren B, Bratt G, Persson C, et al.: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994, 7:220-229.
4. Kundu SK, Katzenstein D, Moses IE, Merigan TC: Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992, 89:11204-11208.
5. Merigan TC, Kundu SK: Human immunodeficiency virus envelope glycoproteins. J Acquir Immune Defic Syndr 1994, 7 (suppl 1):S14-S20.
6. Cheingsong-Popov R, Panagiotidi C, Bowcock S, et al.: Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical course of HIV infection. BMJ 1991, 302:23-26.
7. Lenouillet E, Blanes N, Coutellier A, Demarquest J, Rozenbaum W, Gluckman W: Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker. J Infect Dis 1992, 166:611-616.
8. Tarzadegan H, Chmiel JS, Odaka N, et al.: Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number, and AIDS-free time. J Infect Dis 1992, 166:1217-1222.
9. Pedersen C, Meilsen CM, Vestergard BF, Gerstoff J, Krogsgaard K, Nielsen JO: Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. BMJ 1987, 295:567-569.
10. Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain J-P: The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Synder 1991, 4:704-712.
11. Pontesilli O, Carlesimo M, Varani AR: In vitro lymphocyte proliferative response to HIV-1 p24 is associated with a lack of CD4+ cell decline. AIDS Res Hum Retroviruses 1994, 10:113-114.
12. Pontesilli O, Carlesimo M, Varani AR, et al.: HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol 1995, 100:419-424.
13. Trauger RJ, Giermakowska WK, Ferre E, et al.: Cell-mediated immunity to HIV-1 in Walter-Reed stages 1-6 individuals: correlation with virus burden. Immunology 1993, 78:611-615.
14. Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE: CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci USA 1989, 86:1993-1997.
15. Krowka JE, Stites DP, Jain S, et al.: Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989, 83:1198-1203.
16. Manca F, Habersaw JA, Dalgleish AG: HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4. Lancet 1990, 355:811-815.
17. Adams SE, Dawson KM, Gull K, Kingsman SM, Kingsman AJ: The expression of hybrid HIV:Ty virus-like particles in yeast. Nature 1987, 329:68-70.
18. Adams SE , Senior JM, Kingsman SM, Kingsman AJ: Induction of HIV antibodies by Ty:HIV hybrid virus-like particles. In Technological Advances in Vaccine Development. Edited by Lasky L. New York: Alan R Liss; 1988:117- 126.
19. Mills KHG, Kitchin PA, Mahon BP, et al.: HIV p24-specific helper T cell clones from immunised primates recognize highly conserved regions of HIV-1. J Immunol 1990, 144:1677-1683.
20. Weber J, Cheinsong-Popov R, Callow D, et al.: Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995, 13:831-834.
21. Layton GT, Harris SJ, Myhan J, et al.: Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 1996, 87:171-178.
22. Clerici M, Landay AL, Kessler HA, et al.: Reconstitution of long term T-helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis 1992, 166:723-730.
23. French MAH, Mallal SA, Dawkins RE: Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992, 6:1293-1297.
24. Ranki A, Mattinen S, Yarchoan R, et al.: T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989, 3:63-69
25. Martin SJ, Vyrakarnam A, Cheingsong-Popov R, et al.: Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24 specific cellular and humoral immune responses. AIDS 1993, 7:1315-1323.
26. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
27. Bell SM, Cooprer DA, Kemp BE, et al.: Definition of an immunodominant T cell epitope contained in envelope gp41 sequence of HIV-1. Clin Exp Immunol 1992, 87:37-45.
28. Kniker WT, Anderson CT, McBryde JL, Roumianzeff M, Lesourd B. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the USA. Ann Allergy 1984, 52:75-82.
29. Hickie C, Hickie I, Silove D, Wakefield D, Lloyd A: Delayed-type hypersensitivity skin testing: normal values in the Australian population. Int J Immunopharmacol 1995, 17:629-634.
30. Maxwell AP, McCluskey DR: Assessment of cell-mediated immunity in a British population using multiple skin test antigens. Clin Allergy 1986, 16:365-369.
31. Frazer IH, Collins EJ, Fox JS, Jones B, Oliphant RC, Mackay IR: Assessment of delayed-type hypersensitivity in man: a comparison of the 'multitest' and conventional intradermal injection of six antigens. Clin Immunol Immunopathol 1985, 35:182-190.
32. Smith DE, Boag E, Colebunders R, et al.: Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection does not alter CD4 decline [abstract]. AIDS 1996, 10 (suppl 2):S14.
33. Veenstra I, Williams IG, Colebunder R, et al.: Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis 1996, 174:862-866.
34. Perelson AS, Neumann AU, Markowitz M, Leonard M, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
35. Panteleo G, Fauci A: New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995, 13:487-512.
36. Birx DL, Davis C, Ruiz N, et al.: Results of a phase II double-blinded, multicenter, placebo controlled HIV therapeutic vaccine trial. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA275].
37. Isoukas CM, Rabud J, Sclech RJ, et al.: Active immunisation of patients with HIV infection: a controlled study of the effect of Vaxsyn on progression of immune deficiency. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA274].
38. Eron Jr JJ , Ashby MA, Giordano MF, et al.: Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996, 348:1547-1551.